本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）于 2026 年 1 月 30 日接到控 股股东淄博金城实业投资股份有限公司（以下简称"金城实业"）的通知，其持有的本 公司部分股份办理质押展期业务，具体情况如下： 证券代码：300233 证券简称：金城医药 公告编号：2026-006 山东金城医药集团股份有限公司 关于控股股东部分股份质押展期的公告 | 金城 | 78,552,1 | | 20.46% | 17,588, | 17,588, | 22.39% | 4.58% | 0 | 0 | 0 | 0 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 实业 | | 54 | | 900 | 900 | | | | | | | | 赵鸿富 | 6,676,50 | 0 | 1.74% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | 赵叶青 | 7,227,50 | 0 | 1.88% ...

Core Viewpoint - Jincheng Pharmaceutical expects a significant decline in net profit for the fiscal year 2025, projecting a decrease of 73.07% to 79.67% compared to the previous year [1] Financial Projections - The net profit attributable to shareholders is estimated to be between 40 million to 53 million yuan [1] - The net profit after deducting non-recurring gains and losses is projected to be between 28 million to 37 million yuan, reflecting a decline of 79.43% to 84.44% year-on-year [1] - The impact of non-recurring gains and losses on net profit is estimated to be between 12 million to 16 million yuan [1]

证券代码：300233 证券简称：金城医药 公告编号：2026-004 山东金城医药集团股份有限公司 关于计提资产减值准备的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本次计提资产减值准备情况概述 为更加真实、准确地反映公司截至2025年12 月31 日的财务状况及2025年度 的经营成果，根据《企业会计准则》和相关会计政策的规定，公司对2025年末 合并报表范围内的各类资产进行了减值测试，对截至 2025年12月31日存在减值 迹象的相关资产计提相应的减值准备。 二、本次计提资产减值准备的资产范围、总金额和计入的报告期 公司对合并报表范围内2025年末存在减值迹象的资产，计提各项资产减值 准备5,566.24万元，详见下表： 单位：万元 | 项目 | 本报告期计提减值金额 | | --- | --- | | 存货 | 3,288.82 | | 无形资产 | 1,189.61 | | 固定资产 | 1,087.81 | | 合计 | 5,566.24 | 本次计提资产减值准备计入的报告期间为 2025 年 1 月 1 日至 2025 年12 月 ...

2、业绩预告情况：预计净利润为正值且属于同向下降 50%以上情形。 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务 所审计。公司已就业绩预告有关事项与年报审计会计师事务所进行了预沟通， 公司与会计师事务所在本报告期的业绩预告方面不存在重大分歧，具体数据以 审计结果为准。 山东金城医药集团股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300233 证券简称：金城医药 公告编号：2026-005 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 单位：万元 项 目 本报告期 上年同期 归属于上市公司股东的净利润 4,000～5,300 19,678.08 比上年同期下降 79.67%～73.07% 扣除非经常性损益后的净利润 2,800～3,700 17,990.45 比上年同期下降 84.44%～79.43% 四、其他相关说明 本次业绩预告相关财务数据是公司财务部门初步测算的结果，未经审计机 构审计，具体财务数据 ...

关于签署权益许可和经销协议之补充协议的公告 证券代码：300233 证券简称：金城医药 公告编号：2026-003 山东金城医药集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本协议的签署不会对公司本年度财务状况及经营业绩构成重大影响。 2、本次合作不构成关联交易，亦不构成重大资产重组。 一、协议签署情况 2025 年 5 月山东金城医药集团股份有限公司（以下简称"公司"或"金城医药"） 与 Theramex HQ UK Limited (以下简称"Theramex")签署了《权益许可和经销协 议》，双方就用于绝经后妇女雌激素缺乏症状的激素替代疗法（HRT）的雌二醇黄 体酮软胶囊（以下简称"Bijuva®"）在中国境内的权益许可和经销协议达成合作， 公司获得该产品在中国大陆、香港和澳门的独家排他的商业化权益。 近日，公司与 Theramex 就绝经后妇女雌激素缺乏症状的激素替代疗法（HRT） 和绝经后妇女的骨质疏松症等领域产品（以下简称"合作产品"）在中国境内的权 益许可和经销事宜进一步达成合作，并签署《权益许可和经销协议之补 ...

Group 1 - The core point of the article is that Jincheng Pharmaceutical (300233) reported a total of 29,110 shareholders as of January 20, 2026 [1]

Group 1 - The core point of the article is that Jincheng Pharmaceutical has received approval for a supplemental application for injectable Cefuroxime Sodium from the National Medical Products Administration [2] Group 2 - Jincheng Pharmaceutical's subsidiary, Guangdong Jincheng Jinsuo Pharmaceutical Co., Ltd., is the entity that received the approval [2]

Group 1: Profit Forecasts - Limin Co. expects a net profit of 465 million to 500 million yuan for 2025, representing a year-on-year increase of 471.55% to 514.57% [1] - Guohui Energy anticipates a net profit of 1.32 billion to 1.47 billion yuan for 2025, reflecting a decline of 50.03% to 55.13% year-on-year [2] - Jiajia Yue forecasts a net profit of 198 million to 228 million yuan for 2025, indicating a growth of 50.06% to 72.79% year-on-year [3] - Xianghe Industry projects a net profit of 120 million to 148 million yuan for 2025, with an expected increase of 59.17% to 96.31% year-on-year [4] - Aojie Technology predicts a net profit of 90 million to 120 million yuan for 2025, showing a growth of 228.34% to 337.79% year-on-year [14] - Shanghai Electric expects a net profit of 1.1 billion to 1.32 billion yuan for 2025, representing an increase of approximately 47% to 76% year-on-year [15] - Tianfu Communication anticipates a net profit of 1.881 billion to 2.15 billion yuan for 2025, reflecting a growth of 40% to 60% year-on-year [16] - Yichang Technology forecasts a net profit of 150 million to 225 million yuan for 2025, indicating a year-on-year increase of 58% to 138% [29] - Shanghai Yizhong expects a net profit of 60 million to 70 million yuan for 2025, representing a significant increase of 760.18% to 903.54% year-on-year [41] Group 2: Loss Forecasts - Kexin Electromechanical anticipates a net profit of 55 million to 70 million yuan for 2025, reflecting a decline of 58.65% to 67.51% year-on-year [11][12] - Kexin Technology expects a net loss of 900 million to 1.2 billion yuan for 2025, which is an increase in loss of 78.67% to 84% year-on-year [10] - Tianyang New Materials forecasts a net loss of 250 million to 180 million yuan for 2025, compared to a loss of 213 million yuan in the previous year [20] - Bo Rui Data anticipates a net loss of 90 million to 100 million yuan for 2025, which is an increase in loss of 15.17 million to 25.17 million yuan year-on-year [19] - Xinlian Integrated expects a net loss of 577 million yuan for 2025, which is a reduction in loss of approximately 40.02% compared to the previous year [40] - Fangshilong forecasts a net loss of 4 million to 6 million yuan for 2025 [30] Group 3: Strategic Developments - Lianlong signed a strategic framework agreement with Runyinglian to enhance the reliability and efficiency of the lubricant additive supply chain in China and the Asia-Pacific region [7] - Han Jian Heshan is planning to acquire a 52.51% stake in Liaoning Xingfu New Materials Co., Ltd., with stock suspension expected for up to 9 trading days [13] - Kai Zhong Precision plans to invest 116 million yuan in a technical transformation and expansion project to meet future capacity demands [34] - Tianfu Communication is expected to engage in clinical trials for its ABA001 injection, which has received approval from the National Medical Products Administration [17]

Core Viewpoint - Jincheng Pharmaceutical (300233) announced the approval of a supplemental application for injectable Cefuroxime Sodium by the National Medical Products Administration, indicating a significant development in its product portfolio [1] Group 1: Product Approval - The approved drug, injectable Cefuroxime Sodium, is primarily used for treating infections caused by bacteria sensitive to Cefuroxime, including respiratory and ENT infections, urinary tract infections, skin and soft tissue infections, sepsis, meningitis, and bone and joint infections [1]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced that its subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the supplemental application of injectable Cefuroxime Sodium, a proprietary drug of the company [1] Group 1: Product Information - Injectable Cefuroxime Sodium is a proprietary drug (reference formulation) produced using technology and raw materials from ACS DOBFAR S.P.A [1] - The drug is primarily indicated for infections caused by bacteria sensitive to Cefuroxime, including respiratory and ENT infections, urinary tract infections, skin and soft tissue infections, sepsis, meningitis, and bone and joint infections [1] - Additionally, this product can be used for infection prevention before or during surgical procedures, such as abdominal, pelvic, orthopedic, cardiac, pulmonary, esophageal, vascular, and total joint replacement surgeries [1]